Although it is unlikely that novel adjuvants would be used in the context of the current pandemic, the SARS-CoV-2 pandemic offers an opportunity to reflect on the potential of nanotechnology for vaccine adjuvant development. In this context, it is critical to stream coherent pipelines covering in vitro and in vivo experiments specifically to select candidate materials that might be tested for clinical implementation as vaccine adjuvants.90